Inverse psoriasis, also known as intertriginous or flexural psoriasis, remains a challenging condition to treat. For decades, the mainstay therapy approach has been low-potency steroids for short durations due to the risk of cutaneous atrophy and striae. Other topical options include immunomodulators, vitamin D analogues, and tar-based products. In this paper, we review the literature on the treatment options available for inverse psoriasis.
KundakciN.TursenU.BabikerM.O.GurgeyE.. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients.Int J Dermatol.2002; 41(4): 220–4.
2.
WangG.LiC.GaoT.LiuY.. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study.Eur J Dermatol.2005; 15(3): 176–8.
3.
WozelG.. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.Clin Dermatol.2008; 26(5): 448–59.
4.
LebwohlM.FreemanA.ChapmanM.S.FeldmanS.HartleJ.HenningA.. Proven efficacy of tacrolimus for facial and intertriginous psoriasis.Arch Dermatol.2005; 141(9): 1154.
5.
KalbR.E.BagelJ.KormanN.J.Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation.J Am Acad Dermatol.2009; 60(1): 120–4.
6.
ZonneveldI.M.RubinsA.JablonskaS.Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.Arch Dermatol.1998; 134(9): 1101–2.
7.
LebwohlM.. A clinician's paradigm in the treatment of psoriasis.J Am Acad Dermatol.2005; 53(1 Suppl 1): S59–69.
8.
FreemanA.K.LinowskiG.J.BradyC.Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.J Am Acad Dermatol.2003; 48(4): 564–8.
9.
BruneA.MillerD.W.LinP.Cotrim-RussiD.PallerA.S.. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients.Pediatr Dermatol.2007; 24(1): 76–80.
10.
Martin EzquerraG.Sanchez ReganaM.Herrera AcostaE.Umbert MilletP.. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques.J Drugs Dermatol.2006; 5(4): 334–6.
11.
LebwohlM.FreemanA.K.ChapmanM.S.Tacrolimus ointment is effective for facial and intertriginous psoriasis.J Am Acad Dermatol.2004; 51(5): 723–30.
12.
GribetzC.LingM.LebwohlM.Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.J Am Acad Dermatol.2004; 51(5): 731–8.
13.
KreuterA.SommerA.HyunJ.1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.Arch Dermatol.2006; 142(9): 1138–43.
14.
DelescluseJ.van der EndtJ.D.. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema.Cutis.1996; 57(2 Suppl): 32–8.
15.
FriedlanderS.F.HebertA.A.AllenD.B.. Fluticasone Pediatrics Safety Study G. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months.J Am Acad Dermatol.2002; 46(3): 387–93.
16.
KellyJ.W.CainsG.D.RallingsM.GilmoreS.J.. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses.Australas J Dermatol.1991; 32(2): 85–91.
17.
LebwohlM.. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema.Cutis.1996; 57(2 Suppl): 62–8.
18.
LebwohlM.PeetsE.ChenV.. Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy.Int J Dermatol.1993; 32(11): 830–1.
19.
LebwohlM.G.TanM.H.MeadorS.L.SingerG.. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas.J Am Acad Dermatol.2001; 44(1): 77–82.
20.
KienbaumS.LehmannP.RuzickaT.. Topical calcipotriol in the treatment of intertriginous psoriasis.Br J Dermatol.1996; 135(4): 647–50.
21.
DuwebG.A.EldebaniS.AlhaddarJ.. Calcipotriol cream in the treatment of flexural psoriasis.Int J Tissue React.2003; 25(4): 127–30.
22.
OrtonneJ.P.HumbertP.NicolasJ.F.Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.Br J Dermatol.2003; 148(2): 326–33.
23.
ZeichnerJ.A.. Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas.J Clin Aesthet Dermatol.2010; 3(9): 37–40.
MafongE.A.FriedmanP.M.KauvarA.N.BernsteinL.J.Alexiades-ArmenakasM.GeronemusR.G.. Treatment of inverse psoriasis with the 308 nm excimer laser.Dermatol Surg.2002; 28(6): 530–2.
26.
HornE.J.DommS.KatzH.I.Topical corticosteroids in psoriasis: strategies for improving safety.J Eur Acad Dermatol Venereol.2010; 24(2): 119–24.
27.
MeeuwisK.A.de HulluJ.A.MassugerL.F.van de KerkhofP.C.van RossumM.M.. Genital psoriasis: A systematic literature review on this hidden skin disease.Acta Derm Venereol.2011; 91(1): 5–11.
